Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab - PubMed (original) (raw)
Clinical Trial
. 2008 Jun 15;111(12):5530-6.
doi: 10.1182/blood-2008-01-136242. Epub 2008 Apr 14.
Peter McLaughlin, Rima M Saliba, Chitra Hosing, Martin Korbling, Ming S Lee, L Jeffrey Medeiros, Luis Fayad, Felipe Samaniego, Amin Alousi, Paolo Anderlini, Daniel Couriel, Marcos de Lima, Sergio Giralt, Sattva S Neelapu, Naoto T Ueno, Barry I Samuels, Fredrick Hagemeister, Larry W Kwak, Richard E Champlin
Affiliations
- PMID: 18411419
- PMCID: PMC4624452
- DOI: 10.1182/blood-2008-01-136242
Clinical Trial
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
Issa F Khouri et al. Blood. 2008.
Erratum in
- Blood. 2009 Feb 12;113(7):1613
Abstract
Nonmyeloablative stem cell transplantation in patients with follicular lymphoma has been designed to exploit the graft-versus-lymphoma immunity. The long-term effectiveness and toxicity of this strategy, however, is unknown. In this prospective study, we analyzed our 8-year experience. Patients received a conditioning regimen of fludarabine (30 mg/m(2) daily for 3 days), cyclophosphamide (750 mg/m(2) daily for 3 days), and rituximab (375 mg/m(2) for 1 day plus 1000 mg/m(2) for 3 days). They were then given an infusion of human leukocyte antigen-matched hematopoietic cells from related (n = 45) or unrelated donors (n = 2). Tacrolimus and methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. Forty-seven patients were included. All patients experienced complete remission, with only 2 relapses. With a median follow-up time of 60 months (range, 19-94), the estimated survival and progression-free survival rates were 85% and 83%, respectively. All 18 patients who were tested and had evidence of JH/bcl-2 fusion transcripts in the bone marrow at study entry experienced continuous molecular remission. The incidence of grade 2-IV acute GVHD was 11%. Only 5 patients were still undergoing immunosuppressive therapy at the time of last follow-up. We believe that the described results are a step forward toward developing a curative strategy for recurrent follicular lymphoma.
Figures
Figure 1
Peripheral blood CD19+ recovery after transplantation.
Figure 2
Proportion of patients with normal immunoglobulin (Ig) levels after transplantation.
Figure 3
OS (solid line) and PFS were 85% and 83%, respectively, with a median follow-up of 60 months (range, 19-94 months).
Figure 4
Incidence of severe acute GVHD after nonmyeloablative stem cell transplantation.
Figure 5
Incidence (—) and survival duration (----) of patients with chronic extensive and limited GVHD.
Comment in
- Nonmyeloablative conditioning for relapsed follicular lymphoma.
van Besien K, Hari P. van Besien K, et al. Blood. 2008 Sep 15;112(6):2585-6; author reply 2586-7. doi: 10.1182/blood-2008-06-162800. Blood. 2008. PMID: 18779408 No abstract available.
Similar articles
- Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, Vose JM, Negrin RS, Laport GG. Tomblyn MR, et al. Biol Blood Marrow Transplant. 2011 Jul;17(7):1051-7. doi: 10.1016/j.bbmt.2010.11.004. Epub 2010 Nov 10. Biol Blood Marrow Transplant. 2011. PMID: 21073974 Free PMC article. Clinical Trial. - Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.
Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE. Khouri IF, et al. Blood. 2001 Dec 15;98(13):3595-9. doi: 10.1182/blood.v98.13.3595. Blood. 2001. PMID: 11739162 Clinical Trial. - Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T, Longo W, Devine SM, Nademanee A, Gersten I, Horowitz M, Lazarus HM, Riches ML; Blood and Marrow Transplant Clinical Trials Network. Laport GG, et al. Biol Blood Marrow Transplant. 2016 Aug;22(8):1440-1448. doi: 10.1016/j.bbmt.2016.04.014. Epub 2016 Apr 23. Biol Blood Marrow Transplant. 2016. PMID: 27118571 Free PMC article. Clinical Trial. - Allogeneic stem cell transplantation in follicular lymphoma.
Khouri IF. Khouri IF. Best Pract Res Clin Haematol. 2011 Jun;24(2):271-7. doi: 10.1016/j.beha.2011.03.008. Epub 2011 May 5. Best Pract Res Clin Haematol. 2011. PMID: 21658623 Free PMC article. Review. - Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma.
Tam CS, Khouri I. Tam CS, et al. Curr Hematol Malig Rep. 2007 Oct;2(4):225-31. doi: 10.1007/s11899-007-0031-1. Curr Hematol Malig Rep. 2007. PMID: 20425374 Review.
Cited by
- Efficacy and safety of outpatient fludarabine, cyclophosphamide, and rituximab based allogeneic hematopoietic cell transplantation in adults with severe aplastic anemia.
Gilmore RM, Abernathy K, Shultes K, Eplin DD, Orton L, Kassim A, Sengsayadeth S, Chinratanalab W, Kim TK, Dholaria B, Jayani RV, Savani BN, McNeer E, Choi L, Gatwood K. Gilmore RM, et al. Bone Marrow Transplant. 2024 Sep;59(9):1275-1279. doi: 10.1038/s41409-024-02323-1. Epub 2024 Jun 15. Bone Marrow Transplant. 2024. PMID: 38879608 Free PMC article. - Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes.
Mohty R, Kharfan-Dabaja MA, Chavez JC. Mohty R, et al. Cancer Manag Res. 2023 Apr 19;15:367-375. doi: 10.2147/CMAR.S368588. eCollection 2023. Cancer Manag Res. 2023. PMID: 37155519 Free PMC article. Review. - Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis.
Kanters S, Ball G, Kahl B, Wiesinger A, Limbrick-Oldfield EH, Sudhindra A, Snider JT, Patel AR. Kanters S, et al. BMC Cancer. 2023 Jan 23;23(1):74. doi: 10.1186/s12885-023-10546-6. BMC Cancer. 2023. PMID: 36690960 Free PMC article. - The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy.
Castagna L, Bono R, Tringali S, Sapienza G, Santoro A, Indovina A, Tarantino V, Di Noto L, Maggio A, Patti C. Castagna L, et al. Front Med (Lausanne). 2022 Dec 6;9:1072192. doi: 10.3389/fmed.2022.1072192. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36561713 Free PMC article. Review. - Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups.
Rey-Búa B, Cabrero M, Bento L, Montoro J, Bastos-Oreiro M, Parody R, Yañez L, Lopez-Godino O, Zanabili J, Herrera P, Gutierrez G, Perez A, Piñana JL, Novelli S, Cortés M, Sureda AM, Caballero D, García-Sancho AM. Rey-Búa B, et al. Cancers (Basel). 2022 Nov 18;14(22):5670. doi: 10.3390/cancers14225670. Cancers (Basel). 2022. PMID: 36428762 Free PMC article.
References
- Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2002;100:3108–3114. - PubMed
- Mandigers CMPW, Verdonck LF, Meijerink JPP, et al. Graft-versus- lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant. 2003;32:1159–1163. - PubMed
- Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667–678. - PubMed
- Khouri IF, Saliba RM, Giralt S, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98:3595–3599. - PubMed
- Shipp MA, Harrington DP, Anderson JR, et al. The International Non- Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987–994. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources